Larimar Therapeutics Sees Unusually High Options Volume (NASDAQ:LRMR)

Larimar Therapeutics, Inc. (NASDAQ:LRMR) was the target of unusually large options trading on Wednesday. Traders purchased 3,744 call options on the company. This represents an increase of 456% compared to the average daily volume of 673 call options.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on LRMR shares. Leerink Partners raised shares of Larimar Therapeutics to a “strong-buy” rating in a research note on Monday, January 5th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Larimar Therapeutics in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, January 22nd. Finally, Lifesci Capital upgraded shares of Larimar Therapeutics to a “strong-buy” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $16.50.

Institutional Investors Weigh In On Larimar Therapeutics

A number of large investors have recently added to or reduced their stakes in LRMR. AQR Capital Management LLC bought a new position in shares of Larimar Therapeutics during the first quarter worth approximately $241,000. Acadian Asset Management LLC acquired a new position in Larimar Therapeutics in the 1st quarter valued at $113,000. Rhumbline Advisers increased its position in Larimar Therapeutics by 15.7% during the 1st quarter. Rhumbline Advisers now owns 65,018 shares of the company’s stock worth $140,000 after buying an additional 8,818 shares during the period. CWM LLC boosted its position in shares of Larimar Therapeutics by 205.0% in the second quarter. CWM LLC now owns 32,652 shares of the company’s stock valued at $94,000 after acquiring an additional 21,948 shares during the period. Finally, Ethic Inc. bought a new stake in shares of Larimar Therapeutics in the second quarter valued at about $187,000. Institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics News Summary

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia and Larimar says topline open‑label data will support a BLA planned for June 2026; company targets a potential U.S. launch in H1 2027. This is the primary fundamental catalyst driving the move. Article Title
• Positive Sentiment: Wedbush reaffirmed an “outperform” rating and set an $11 price target, implying significant upside versus recent levels — a clear analyst vote of confidence that likely supported buying. Article Title
• Positive Sentiment: Lifesci Capital upgraded LRMR to “strong‑buy,” another bullish analyst action adding to demand from institutional and retail investors. Article Title
• Neutral Sentiment: Multiple outlets reported the stock surge and the FDA news, increasing visibility and trading volume (coverage from Investing.com, MSN and AAII). Media amplification can prolong momentum but doesn’t change the underlying clinical/regulatory timeline. Article Title Article Title Article Title Article Title

Larimar Therapeutics Trading Up 46.4%

Shares of Larimar Therapeutics stock traded up $1.71 during trading on Wednesday, hitting $5.40. 22,869,448 shares of the stock were exchanged, compared to its average volume of 3,283,496. The company has a fifty day moving average price of $3.44 and a 200-day moving average price of $3.76. The stock has a market capitalization of $447.17 million, a price-to-earnings ratio of -2.81 and a beta of 1.01. Larimar Therapeutics has a 1-year low of $1.61 and a 1-year high of $5.47.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.